The Effects of Myo-Inositol and B and D Vitamin Supplementation in the db/+ Mouse Model of Gestational Diabetes Mellitus.
journal contribution
posted on 2017-05-02, 09:10 authored by Jasmine F. Plows, Florence Budin, Rebecka A. M. Andersson, Valerie J. Mills, Katherine Mace, Sandra T. Davidge, Mark H. Vickers, Philip N. Baker, Irma Silva-Zolezzi, Joanna L. StanleyGestational diabetes mellitus (GDM) is a growing concern, affecting an increasing number of pregnant women worldwide. By predisposing both the affected mothers and children to future disease, GDM contributes to an intergenerational cycle of obesity and diabetes. In order to stop this cycle, safe and effective treatments for GDM are required. This study sought to determine the treatment effects of dietary supplementation with myo-inositol (MI) and vitamins B2, B6, B12, and D in a mouse model of GDM (pregnant db/+ dams). In addition, the individual effects of vitamin B2 were examined. Suboptimal B2 increased body weight and fat deposition, decreased GLUT4 adipose tissue expression, and increased expression of inflammatory markers. MI supplementation reduced weight and fat deposition, and reduced expression of inflammatory markers in adipose tissue of mice on suboptimal B2. MI also significantly reduced the hyperleptinemia observed in db/+ mice, when combined with supplemented B2. MI was generally associated with adipose tissue markers of improved insulin sensitivity and glucose uptake, while the combination of vitamins B2, B6, B12, and D was associated with a reduction in adipose inflammatory marker expression. These results suggest that supplementation with MI and vitamin B2 could be beneficial for the treatment/prevention of GDM.
Funding
Funding for this study was provided in part by the Nestle Research Center.
History
Citation
Nutrients, 2017, 9 (2)Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGYVersion
- VoR (Version of Record)
Published in
NutrientsPublisher
MDPIissn
2072-6643eissn
2072-6643Acceptance date
2017-02-09Copyright date
2017Available date
2017-05-02Publisher DOI
Publisher version
http://www.mdpi.com/2072-6643/9/2/141Notes
The following are available online at http://www.mdpi.com/2072-6643/9/2/141/s1, Figure S1: Glucose tolerance at GD16.5 of WT and db/+ mice in the control group (normal B2, no added MI). (A) Oral glucose tolerance plots comparing WT and db/+ mice on control diet. There were no differences between WT and db/+ mice on control diet at any time point of the OGTT; (B) The area under the curve of the glucose tolerance plots comparing WT and db/+ mice on control diet. There was no difference between WT and db/+ mice on area under the curve of the OGTT plots. n = 12 mice per group; Figure S2: Glucose tolerance at GD16.5, when supplement groups are pooled together for WT and db/+ mice: (A) Oral glucose tolerance plots comparing all WT and all db/+ mice. There were no differences between WT and db/+ mice when all supplements were pooled at any time point of the OGTT. (B) The area under the curve of the glucose tolerance plots comparing all WT and all db/+ mice. There was no difference between WT and db/+ mice on area under the curve of the OGTT plots; Table S1: Weights of major organs at GD18.5. Data are presented as the mean ± SEM; Table S2: Fetal and placental growth data from WT mothers; Table S3: Fetal and placental growth data from db/+ mothers; Table S4:Language
enAdministrator link
Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC